[1]汤影子,陈耀凯,刘霖,等.阿德福韦酯治疗慢性乙型病毒性肝炎疗效相关因素分析[J].陆军军医大学学报(原第三军医大学学报),2007,29(18):1805-1807.
 TANG Ying-zi,CHEN Yao-kai,LIU Lin,et al.Correlation factors involved in therapeutic efficacy of adefovir dipivoxil for chronic hepatitis B patients[J].J Amry Med Univ (J Third Mil Med Univ),2007,29(18):1805-1807.
点击复制

阿德福韦酯治疗慢性乙型病毒性肝炎疗效相关因素分析(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
29卷
期数:
2007年第18期
页码:
1805-1807
栏目:
论著
出版日期:
2007-09-30

文章信息/Info

Title:
Correlation factors involved in therapeutic efficacy of adefovir dipivoxil for chronic hepatitis B patients
作者:
汤影子陈耀凯刘霖邓国宏王宇明
第三军医大学西南医院全军感染病研究所
Author(s):
TANG Ying-zi CHEN Yao-kai LIU Lin DENG Guo-hong WANG Yu-ming
Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
关键词:
慢性乙型肝炎阿德福韦酯相关因素
Keywords:
Hepatitis Badefovir dipivoxilcorrelation factor
分类号:
R512.62;R969.4;R978.7
文献标志码:
A
摘要:
目的  研究分析影响阿德福韦酯治疗慢性乙型病毒性肝炎疗效的主要相关因素。 方法  收集2004年3月至2006年11月采用贺维力(阿德福韦酯10 mg片剂)治疗的34例慢性乙型病毒性肝炎患者临床资料,分析治疗前血清ALT水平、治疗前HBV DNA水平、体质量、性别等因素与疗效的相关性。 结果  获得HBV DNA阴转的患者较之未阴转患者基线HBV DNA水平较低、ALT较高、获得IVR的比例更高(P=0.034、0.011); 获得HBeAg/抗HBe血清学转换的患者较之未获转换的患者基线HBV DNA水平较低、获得IVR的比例更高(P=0.034);获得IVR的患者较之未获得IVR者基线HBV DNA水平较低、ALT水平较高(P=0.006、0.003)。52、104周及治疗终点HBV DNA下降水平均与体质量呈负相关(P=0.026、0.016、0.035)。 结论  血清HBV DNA水平较低、ALT水平较高、体质量较低的慢性乙型肝炎患者更易对标准阿德福韦酯治疗方案产生病毒学应答,高体质量患者应适当增加给药剂量。
Abstract:
Objective    To investigate the correlation factors associated with the therapeutic efficacy of adefovir dipivoxil for patients with chronic hepatitis B.      Methods    Totally 34 hepatitis B patients with positive HBeAg were enrolled and treated with adefovir dipivoxil (10 mg once daily) for 132 weeks, and the biochemical and virological parameters were monitored. Statistic analysis was used to identify some possible correlation factors associated with therapeutic efficacy.     Results    Patients who achieved undetectable HBV DNA at the end of the treatment were found to have a lower baseline HBV DNA level, higher ALT and higher ratio of initial virologic response (IVR) compared with those who did not achieve (P=0.034, 0.011, <0.001); HBeAg seroconversion were observed more often in patients with lower baseline HBV DNA and those achieving IVR (P=0.034, <0.001); And lower baseline HBV DNA and higher ALT predicted a higher probability for winning IVR (P=0.006, 0.003). Linear regression identified negative correlations between body weight and the reduction level of HBV DNA at the week of 52, 104 and 132 respectively (P=0.026, 0.016, 0.035).      Conclusion    Patients with lower baseline HBV DNA level, higher ALT and lower body weight were more prone to achieve virologic response. Thus, a higher dosage of adefovir dipivoxil is recommended for the patients with higher body weight.

相似文献/References:

[1]王沂芹,柏健鹰,傅晓岚,等.慢性乙型肝炎患者HBV特异性CTL的CD28表达研究[J].陆军军医大学学报(原第三军医大学学报),2006,28(04):342.
[2]谭顺,谭文婷,刘明,等.176例甲型肝炎临床特征分析[J].陆军军医大学学报(原第三军医大学学报),2010,32(22):2409.
 Tan Shun,Tan Wenting,Liu Ming,et al.Clinical characteristics of hepatitis A: report of 176 cases[J].J Amry Med Univ (J Third Mil Med Univ),2010,32(18):2409.
[3]曾波,孙航,刘杞,等.HBV转基因小鼠与正常小鼠CD4+CD25+调节性T细胞数量和功能的比较[J].陆军军医大学学报(原第三军医大学学报),2010,32(14):1499.
 Zeng Bo,Sun Hang,Liu Qi,et al.Comparison of frequency and function of CD4+CD25+ regulatory T cells in HBV transgenic and normal mice[J].J Amry Med Univ (J Third Mil Med Univ),2010,32(18):1499.
[4]杨华,罗亚文,刘华庆,等.慢性乙型肝炎患者肝组织CXCR3及其配体IP 10表达与肝脏炎症程度、纤维化的相关性研究[J].陆军军医大学学报(原第三军医大学学报),2012,34(03):250.
 Yang Hua,Luo Yawen,Liu Huaqing,et al.CXCR3 and IP 10 expression in patients with chronic hepatitis B and their correlation with degree of liver inflammation and hepatic fibrosis[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(18):250.
[5]李玲,毛青,黄燕萍,等.慢性乙型肝炎患者HBV DNA YMDD变异的检测及意义[J].陆军军医大学学报(原第三军医大学学报),2005,27(02):167.
[6]刘俊,蒋业贵,王宇明,等.HLA-DR、-DQ在慢性乙型肝炎肝组织中的表达及其意义[J].陆军军医大学学报(原第三军医大学学报),2004,26(07):0.[doi:10.16016/j.1000-5404.2004.07.005 ]
[7]谭奇亮.促肝细胞生长素与前列腺素E1联合治疗慢性乙型肝炎重度胆汁淤积62例疗效观察[J].陆军军医大学学报(原第三军医大学学报),2004,26(09):0.[doi:10.16016/j.1000-5404.2004.09.038 ]
[8]何登明,毛青,王宇明,等.拉米夫定疗程中慢性乙型肝炎患者血清IL-12水平和Th平衡变化及其意义[J].陆军军医大学学报(原第三军医大学学报),2004,26(19):0.[doi:10.16016/j.1000-5404.2004.19.028 ]
 HE Deng-ming,MAO Qing,WANG Yu-ming,et al.[J].J Amry Med Univ (J Third Mil Med Univ),2004,26(18):0.[doi:10.16016/j.1000-5404.2004.19.028 ]
[9]何念海,马巧玉,顾长海,等.重组干扰素α-2b治疗慢性乙型肝炎的疗效、影响因素及预后研究[J].陆军军医大学学报(原第三军医大学学报),2000,22(04):0.[doi:10.16016/j.1000-5404.2000.04.032 ]
 HE Nian-hai,MA Qiao-yu,GU Chang-hai.[J].J Amry Med Univ (J Third Mil Med Univ),2000,22(18):0.[doi:10.16016/j.1000-5404.2000.04.032 ]
[10]何念海,胡大荣,马巧玉,等.无环鸟苷治疗慢性乙型肝炎的疗效随访[J].陆军军医大学学报(原第三军医大学学报),1997,19(02):0.[doi:10.16016/j.1000-5404.1997.02.033 ]

更新日期/Last Update: 2008-07-16